Midazolam inhibits chondrogenesis via peripheral benzodiazepine receptor in human mesenchymal stem cells

Yung-Ching Chen1 | King-Chuen Wu2,3 | Bu-Miin Huang1 | Edmund Cheung So4,5 | Yang-Kao Wang1

1Department of Cell Biology and Anatomy, College of Medicine, National Cheng Kung University, Tainan, Taiwan
2Department of Nursing, Chang Gung University of Science and Technology, Chia-Yi County, Taiwan
3Department of Anesthesiology, Chang Gung Memorial Hospital, Chiayi County, Taiwan
4Department of Anesthesiology, An-Nan Hospital, China Medical University, Tainan, Taiwan
5Department of Medicine, China Medical University, Taichung, Taiwan

Correspondence
Edmund Cheung So and Yang-Kao Wang
Emails: edmansetw@gmail.com and humwang@mail.ncku.edu.tw

Funding information
Ministry of Science and Technology, Grant/Award Number: MOST 105-2320-B-006-030; Chang Gung Memorial Hospital, Chia-Yi, Grant/Award Number: CMRPG6F0291; An Nan Hospital-China Medical University, Grant/Award Number: ANHRF104-01; Academia Sinica, Grant/Award Number: 2396-106-0100

Abstract
Midazolam, a benzodiazepine derivative, is widely used for sedation and surgery. However, previous studies have demonstrated that Midazolam is associated with increased risks of congenital malformations, such as dwarfism, when used during early pregnancy. Recent studies have also demonstrated that Midazolam suppresses osteogenesis of mesenchymal stem cells (MSCs). Given that hypertrophic chondrocytes can differentiate into osteoblast and osteocytes and contribute to endochondral bone formation, the effect of Midazolam on chondrogenesis remains unclear. In this study, we applied a human MSC line, the KP cell, to serve as an in vitro model to study the effect of Midazolam on chondrogenesis. We first successfully established an in vitro chondrogenic model in a micromass culture or a 2D high-density culture performed with TGF-β-driven chondrogenic induction medium. Treatment of the Midazolam dose-dependently inhibited chondrogenesis, examined using Alcian blue-stained glycosaminoglycans and the expression of chondrogenic markers, such as SOX9 and type II collagen. Inhibition of Midazolam by peripheral benzodiazepine receptor (PBR) antagonist PK11195 or small interfering RNA rescued the inhibitory effects of Midazolam on chondrogenesis. In addition, Midazolam suppressed transforming growth factor-β-induced Smad3 phosphorylation, and this inhibitory effect could be rescued using PBR antagonist PK11195. This study provides a possible explanation for Midazolam-induced congenital malformations of the musculoskeletal system through PBR.

KEYWORDS
chondrogenesis, mesenchymal stem cells, Midazolam, peripheral benzodiazepine receptor

1 | INTRODUCTION

Benzodiazepines are widely used sedative drugs for applying regional anaesthesia.1 To obtain more specific functions to treat patients, numerous types of benzodiazepine derivatives have been synthesized. Among them, Midazolam (Dormicum®) is a short-acting benzodiazepine derivative that has been extensively used in surgical procedures, premedication and induction for general anaesthesia. Compared with other types of anaesthetics, pharmacokinetics and the drug mechanism of benzodiazepine are well understood.2,3

In addition to sedation, benzodiazepines possess anticonvulsant, anxiolytic amnestic, hypnosis and centrally mediated muscle relaxation
properties. They produce a sedation effect primarily through modulation of gamma-aminobutyric acid (GABA) receptors in the central nervous system to block nerve impulses. GABA binds with GABAA, GABAB, and GABAC receptors. Among them, the GABAA receptor is of particular significance for psychopharmacology because it contains a variety of binding sites at which behaviour-modifying drugs act to produce some or all of their effects. Benzodiazepines bind to benzodiazepine sites on GABA receptors and allosterically modulate the response of the channel upon GABA binding. The function of benzodiazepines acting on GABAA receptors is to increase the amplitude or decay time of GABA-mediated inhibitory post-synaptic potentials, thus increasing the inhibitory tone of GABAergic synapses to reduce the firing of neuron populations.

In addition to the central nervous system, benzodiazepines act on peripheral tissues performed with peripheral benzodiazepine receptor (PBR) or mitochondria translocator proteins. A PBR is distinct in its pharmacological, anatomical, structural, and physiological aspects when compared with central benzodiazepine receptors. PBR is an 18 kD protein, localize to the mammalian mitochondria membrane, and are highly conserved among various mammalian species in various types of peripheral tissue. It has been shown that PBR distributes ubiquitously in most types of tissues, including bone marrow stromal cells. Putative PBR functions are involved in numerous types of physiological processes, such as steroidogenesis, apoptosis, cell proliferation, regulation of mitochondrial membrane potential, mitochondria respiratory chains, voltage-dependent calcium channels and microglial activation.

Although numerous papers have proved the safety of benzodiazepine and its derivatives, there remain in vitro and in vivo studies indicating the toxic effects that can occur after benzodiazepine treatment. For example, previous study has demonstrated that the incidence rate of congenital malformations was 0.23% if the maternal plasma was diagnosed as benzodiazepine positive. Furthermore, Deck et al. summarized the database of all infants born with major congenital malformations to mothers on antiepileptic drugs from Boston Medical Center from the years 2003 to 2010, including cleft lips/palate, cardiac defects and urogenital defects. Results showed that for women on benzodiazepine monotherapy during pregnancy, major congenital malformations were high and extended to 10.6%. Among their infants, the rate for cleft lip/palate was approximately 0.747%.

In addition, previous studies exposing young mice to benzodiazepine derivatives, either treated alone or together with other chemicals, have resulted in high birth rates of runts, increased retarded ossification of skull bones and a variety of sternal defects. More importantly, Midazolam has been found to inhibit osteogenesis of human bone marrow-derived mesenchymal stem cells (hMSCs). However, the detailed mechanisms for benzodiazepine-regulated bone/cartilage differentiation that associated with foetal growth retardation remain unknown.

As mentioned above, benzodiazepine and its derivatives are associated with birth defects and cleft lip/palates and have been linked to osteotoxicity. Because chondrocytes are the precursors of osteogenesis during musculoskeletal development, we sought to investigate in this study the Midazolam-regulated chondrogenesis of human MSCs and the molecular mechanisms underlying this process.

## MATERIALS AND METHODS

### 2.1 Experimental system

KP cells, an immortalized human MSC line, were established from primary human MSCs, which were transduced using a retroviral vector LXSN-16E6E7. KP cells display similar types of cell surface marker profiles as parental primary human MSCs do and retain the stem-like properties. KP cells can not only renew themselves, but also differentiate into mesenchymal and nonmesenchymal cell lineages without neoplastic transformation under certain conditions.

This type of cell line has been used in studies of stem cell biology and regenerative medicine. The cell line used in this study was kindly provided by Dr. Shih-Chieh Hung (China Medical University). We also purchased primary human bone marrow-derived MSCs from Lonza Walksville Inc., which were maintained in growth medium: DMEM low glucose containing 10% foetal bovine serum (GIBCO with selected lot), 100 units/mL penicillin and 100 μg/mL streptomycin (both from GIBCO) at 37°C with a humidified 5% CO2 atmosphere and medium was changed twice a week. Only early passages (passages 3-6) of primary hMSCs were used in this experiment.

To induce chondrogenic differentiation, KP cells or hMSCs were treated with chondrogenic induction medium (DMEM low glucose, 0.1 μmol/L Dexamethasone, 50 μmol/L L-ascorbic acid-2-phosphate, 1× Insulin-Transferrin-Selenium, 40 μg/mL L-proline, 100× L-glutamine, 5 ng/mL transforming growth factor-β3). For the pellet culture, 3 × 10^6 cells per pellet were placed in a 15-mL centrifuge tube and centrifuged to produce a pellet. The medium was changed every 3 days. For high-density cultures, cells were seeded at 3 × 10^4 cells/cm² overnight and the medium was replaced with chondrogenic induction medium the following day.

The chondrogenic differentiation was accessed after 7 or 14 days of treatment.

### 2.2 Alcian blue staining and quantification

Cells in the pellet culture or at high densities were rinsed with PBS and fixed with 4% paraformaldehyde for 10 minutes. After fixation, cells were rinsed twice with PBS and then stained with 1% Alcian blue for 30 minutes and rinsed in PBS until the blue colour was removed from the negative control cells. The amount of Alcian blue stained glycosaminoglycan (GAG) was quantified as per Woods et al, with modification, by dissolving the stained GAG in 6 mol/L...
guanidine hydrochloride overnight at 4°C. The absorbance of dissol
solved stained GAG was then quantified using a spectrophotome
ter at OD 620 nm.33

2.3 | Western blot analysis

After treatment, cells were rinsed twice using chilled PBS and then
lysed and collected using a radioimmunoprecipitation assay buffer
(Thermo) plus protease and phosphatase inhibitor cocktails (Thermo).
After sonication, cell lysate was centrifuged at 15,000 × g for 30
minutes at 4°C and supernatant was collected in an eppendorf
tube and stored at −80°C. Protein concentration was assessed using
a bicinchoninic acid protein assay (Bio-Rad) as per the manufac-
turer’s instructions. Fifteen to thirty µg of protein was resolved using
SDS-PAGE, followed by electro-transferred onto a methanol-soaked
polyvinylidene fluoride (PVDF) membrane. The PVDF membrane was
blocked with 5% milk or 2% bovine serum albumin (for phosphory-
lated protein) in Tris-Buffered Saline-Tween 20 (TBST) and then
incubated with primary antibody overnight at 4°C. The membrane
was then rinsed with TBST and the immunocomplex on membrane
was detected using horse-radish peroxidase-conjugated secondary
antibody, and the final immunocomplexes were visualized using fluo-
rescence microscope or confocal microscope (Olympus FV-1000).

2.4 | Immunostaining and immunofluorescence

Cells in micropellet cultures were fixed with 4% paraformaldehyde,
washed in PBS and then sectioned and frozen (LEICA CM 1950).
The 10-µm-thick sections were rinsed twice in PBS, followed by
soaking in SuperBlock blocking buffer (Thermo) for 1 hour at room
temperature, and then incubated with primary antibody overnight
at 4°C. The sections were then rinsed twice with PBS and stained with
secondary antibody conjugated with Alexa 594 (Thermo). Images
were taken using an Olympus epifluorescence microscope. For high-
density cultures, cells were rinsed twice with PBS and then fixed
with 4% paraformaldehyde, soaked in SuperBlock blocking buffer
(Thermo) for 1 hour at room temperature and then incubated with
primary antibodies overnight at 4°C. The sections were then rinsed
twice with PBS and stained with secondary antibody conjugated
Alexa 594 (Thermo). Images were taken using an Olympus epifluo-
rescence microscope or confocal microscope (Olympus FV-1000).

2.5 | Transfection of small interfere RNA

Small interference RNA (siRNA) (ON-TARGETplus™ siRNA Smart-
pool) specifically against human PBR was purchased from GE Dhar-
macon RNAi Technologies, and the transfection of siRNA (5 nmol/L)
was performed using a Lipofectamine 2000 transfaction reagent
(Thermo Fisher Sci) as per manufacturer instructions. siRNA with a
scrambled RNA sequence (siN) served as a transfection control. The
protein levels of PBR in MSCs after siRNA transfection were
detected using Western blot analysis.

2.6 | Statistics

All quantified results are shown in mean ± SEM of three to four
independent experiments. Statistical analyses were performed using
ANOVA followed by Tukey’s test for significant difference. Signifi-
cance was accepted when P < .05.

3 | RESULTS

3.1 | Establishment of chondrogenic differentiation

We first established an in vitro chondrogenic model using either
micropellet or high cell density cultures. KP cells were treated with
or without transforming growth factor-β3 (TGF-β) containing chon-
drogenic induction medium for 14 days; the chondrogenic differenti-
ation was examined using Alcian blue staining to stain GAGs or by
immunostaining of type II collagen. Results demonstrated that with-
out chondrogenic induction, the morphology of the micropellets
showed incomplete structures and fractures in the centre of pellets
(C), whereas pellets treated with chondrogenic induction medium
showed a condensed morphology (CHON) (Figure 1A). In control
pellets, cells were lightly stained using Alcian blue, whereas chondro-
genic induction medium-treated micropellets (CHON) were strongly
stained (Figure 1A). In addition to the expression of GAG, we also
examined the expression of type II collagen in micropellets per-
formed with immunostaining. The results showed that the staining
of type II collagen was not clear in control cells, but chondrogenic
induction medium-treated cells (CHON) (Figure 1C), but not in con-
trol cells (C). These results suggest that in vitro chondrogenic differ-
entiation was successfully established and can be used in further
studies.

3.2 | Midazolam inhibits chondrogenic differentiation

To test for Midazolam-inhibited hMSC chondrogenesis, KP cells
either in micropellets or in high-density cultures were treated with-
out (C) or with TGF-β-containing chondrogenic induction medium
(CHON) in the presence of different doses of Midazolam (1, 10 and
20 µmol/L, denoted as CHON + MDZ1, CHON + MDZ10 and
CHON + MDZZ20, respectively). The Midazolam only group at dose
of 10 µmol/L (MDZ10) was used as a negative control. The chondro-
genic differentiation was analysed using Alcian blue, immunostaining
of type II collagen as previously described. TGF-β-containing chon-
drogenic induction medium significantly increased Alcian blue con-
tent in micropellet cultures, and this chondrogenic induction was
dose-dependently inhibited by the treatment of Midazolam (Fig-
ure 2A,B). Similar results from the immunostaining of type II collagen
can be observed in Figure 2C. At high cell density cultures, the
chondrogenic differentiation was inhibited by Midazolam dose-dependently (Figure S1). Early studies have indicated that SOX trios (SOX5, SOX6 and SOX9) are crucial for chondrogenesis. To further characterize Midazolam-inhibited protein levels of chondrogenic markers, we performed Western blot analysis to examine the protein levels of SOX5, SOX6, SOX9 and type II collagen. KP cells were seeded at density of $3 \times 10^5$ cells/cm$^2$ and were treated with or without chondrogenic differentiation medium in the presence of various doses of Midazolam (1, 10 and 20 μmol/L) for 7 days. The chondrogenic induction successfully increased the protein levels of SOX9 and type II collagen, whereas Midazolam significantly inhibited protein levels of SOX9 and type II collagen (Figure 2D-F). Interestingly, the chondrogenic induction did not affect the protein levels of SOX5/SOX6 and treatment of Midazolam did not alter the protein

**FIGURE 1** Establishment of chondrogenesis by micropellet and high-density culture of mesenchymal stem cells. The KP cells were trypsinized and cell number was counted. About $3 \times 10^5$ cells were used and centrifuged at 150 $\times$ g to make a micropellet. For chondrogenic induction, the micropellets were treated with or without chondrogenic induction medium for 14 d. The chondrogenic differentiation was accessed using (A) Alcian blue staining and (B) type II collagen immunofluorescence staining. (C) Chondrogenic differentiation of KP cells at high-density culture ($3 \times 10^4$ cells/cm$^2$) for 14 d in the presence or absence of chondrogenic induction medium. Chondrogenesis was assessed using Alcian blue staining and immunofluorescence staining of type II collagen. Scale bar: (A) 400 μm, (B, C) 200 μm. The nuclei were stained with DAPI

Type II collagen/DAPI

Alcian blue
levels SOX5/6. These results demonstrate that Midazolam-inhibited chondrogenic differentiation is mediated by the inhibition of the expression of chondrogenic-associated proteins.

3.3 | Midazolam inhibits chondrogenic differentiation of primary mesenchymal stem cells

Given that KP cells have been transfected using exogenous genes to maintain MSC stemness, whether the incorporated genes produce different responses in these cells remain unclear. To test the inhibitory effects of Midazolam in chondrogenesis, we performed primary hMSCs to evaluate the results that were obtained from the KP MSC cell line. Primary hMSCs were seeded at a high density (3 x 10^4 cells/cm^2) with or without chondrogenic induction medium in the presence of Midazolam (0, 1, 10 and 20 μmol/L) at the indicated time, and chondrogenic differentiation was evaluated using Alcian blue staining and immunostaining of type II collagen. Similar to the results that were obtained from KP MSCs, chondrogenic induction medium successfully induced an increase in Alcian blue staining, whereas Midazolam inhibited Alcian blue staining dose-dependently (Figure 3A,B). In addition, chondrogenic induction-induced type II collagen was dose-dependently inhibited by the treatment of Midazolam (Figure 3C). Similar was confirmed using micropellet culture of primary hMSCs (Figure S2). Together, these results demonstrate that Midazolam-inhibited chondrogenic differentiation is reproducible in MSCs from different sources.
chondrogenesis was mediated by PBR. We first examined PBR inhibitor PK11195 on the effect of Midazolam on chondrogenesis. Primary hMSCs were seeded at a high density (3 x 10^4 cells/cm^2) with or without chondrogenic induction medium in the presence of Midazolam (10 μmol/L) and co-treated with PK11195 (0, 0.1, 1 and 10 μmol/L) for 7 days. The chondrogenic differentiation was accessed using Alcian blue staining and immunostaining of type II collagen. We found that treatment of PK11195 using a 10 μmol/L dose significantly improved the Midazolam-inhibited effect on chondrogenic differentiation (Figure 4A,B). Similar results were obtained using immunostaining with type II collagen (Figure 4C).

Our results indicate that treatment of cells with a higher dose of PK11195 (20 μmol/L) resulted in a decrease in cell number, which represented an off-target effect of PK11195 (data not shown). We therefore performed siRNA specific to PBR to elucidate the effect of PBR in our model. The control (siRNA with a scrambled sequence, siN, 5 nmol/L) or siPBR (5 nmol/L) was transfected into primary hMSCs. Protein levels of PBR after siRNA transfection were determined using Western blot analysis, and the results showed the successful knockdown by siPBR of the endogenous PBR protein levels (Figure 5A) without altering cell numbers (data not shown). The transfected primary MSCs were then seeded at a high density (3 x 10^4 cells/cm^2) in the presence of chondrogenic medium with or without Midazolam (10 μmol/L) for 7 days. The chondrogenic differentiation was determined using Alcian blue staining (Figure 5B,C) and immunostaining of type II collagen (Figure 5D). Transfection of scrambled siRNA did not rescue Midazolam-suppressed Alcian blue and type II collagen content during chondrogenesis. In addition, knockdown of PBR (siPBR) rescued the Midazolam-inhibited chondrogenic differentiation (Figure 5). Similar results were found using Western blot to detect the protein levels of SOX9 and type II collagen (Figure 5E-G). However, knockdown of PBR did not affect the protein levels of SOX5/SOX6. These results suggest that inhibition of PBR by either PK11195 or siRNA rescues Midazolam-suppressed chondrogenic differentiation, which indicates that PBR mediates Midazolam-inhibited chondrogenic differentiation.

To further characterize that Midazolam inhibits chondrogenesis via inhibition of TGF-β signalling, we assessed the phosphorylation of Smad3, one of the major downstream signalling molecules of TGF-β.36 We found that administration of Midazolam significantly suppressed TGF-β-induced Smad3 phosphorylation dose-dependently (Figure 6A). Interestingly, if cells were co-treated with PBR antagonist PK11195, the Midazolam-induced suppression of Smad3 phosphorylation could be rescued (Figure 6B).

In summary, TGF-β induces Smad3 phosphorylation. Phosphorylated Smad2/3 can interact with Smad4 and translocate into the nucleus to trigger chondrogenic-related gene transcription. Midazolam-induced suppression of chondrogenesis may be mediated by the interaction with PBR, which in turn ameliorates TGF-β-induced Smad signalling.

**FIGURE 3** Midazolam inhibits chondrogenic differentiation in primary mesenchymal stem cells. Primary mesenchymal stem cells were seeded at 3 x 10^4 cells/cm^2 and treated without (C) or with chondrogenic induction medium (CHON) in the presence of various concentrations of Midazolam (1, 10 and 20 μmol/L, denoted as CHON, CHON + MDZ 1, CHON + MDZ 10 and CHON + MDZ 20, respectively) for 7 d. Midazolam only at concentration of 10 μmol/L (MDZ10) was used as a negative control. Chondrogenesis was evaluated using (A) Alcian blue staining and (B) Alcian blue was quantified by dissolving it in guanidine hydrochloride, after which the optical density of the samples was read by a spectrophotometer at OD620 nm. Quantification results are normalized with untreated control. Results are presented as mean ± SEM of three independent experiments (*P ≤ .05, **P ≤ .01, ***P ≤ .005). (C) Immunostaining of type II collagen. Scale bar: (A) 200 μm; (C) 50 μm
4 | DISCUSSION

The present study demonstrates the role of Midazolam in chondrogenesis inhibition. However, other recent studies have demonstrated that chondrocytes are the precursors of osteogenesis, but because they have only demonstrated the possible osteotoxicity of benzodiazepine, the role of Midazolam in chondrogenic differentiation remains unclear. We were interested in whether Midazolam-induced congenital musculoskeletal defects were caused by the inhibition of chondrogenic differentiation. We first demonstrated benzodiazepine derivative Midazolam-inhibited chondrogenic differentiation via PBR in human MSCs. Inhibition of PBR by either PK11195 or siRNA specific to PBR rescued the inhibitory effect of Midazolam. More importantly, Midazolam-inhibited TGF-β-induced SMAD3 phosphorylation was mediated by PBRs. The results provided here indicate that PBR plays a crucial role in Midazolam-inhibited chondrogenesis, which may correlate with congenital malformation in pregnant women who have been treated with benzodiazepine for anxiety or insomnia.

Although benzodiazepine derivatives may cause musculoskeletal defects, the molecular mechanisms of how these benzodiazepine derivatives result in congenital defects remain unknown. To confirm the inhibitory effect of Midazolam, we applied TGF-β-containing chondrogenic induction medium in human MSCs. We used several differentiation markers to indicate chondrogenesis, including SOX9, type II collagen and an increased amount of GAGs, which could be stained using Alcian blue. SOX9 is a transcriptional factor that plays a key role in the regulation of chondrogenesis, and multiple signalling pathways are known to regulate the expression and activity of SOX9 during chondrogenesis. Activated SOX9 in turn regulates chondrogenic-dependent markers, such as type II collagen and aggrecan. In addition, SOX9, together with SOX5 and SOX6 to form SOX trios, and expression of these trios lead to chondrogenesis. In current study, we found that Midazolam inhibits protein levels of SOX9

**FIGURE 4** Peripheral benzodiazepine receptor antagonist PK11195 rescues Midazolam-induced suppression of chondrogenesis. Primary mesenchymal stem cells were seeded at $3 \times 10^5$ cells/cm² and treated without or with chondrogenic induction medium in the presence of Midazolam (10 μmol/L, MDZ10, CHON + MDZ, respectively) or co-treated with PK11195 (0.1, 1 and 10 μmol/L, denoted as PK0.1, PK1 and PK10, respectively) for 7 d. Cells were stained with Alcian blue (A, B) or immunoblotted with type II collagen (C). (B) Quantification of Alcian blue and these quantification results are normalized with untreated control. Representative images are selected from at least three independent experiments. Results are presented as mean ± SEM of three independent experiments ($^{*}P \leq .05$, $^{**}P \leq .01$). Scale bar: 50 μm
but not SOX5 and SOX6 in chondrogenic induction. One possible reason is that SOX9 is found to be one of the TGF-β/Smad3 downstream effectors\textsuperscript{46} to regulate chondrogenesis. The down-regulation of SOX9 may result in disruption of the formation of SOX trio, which in turn inhibits the transcription of chondrogenesis-related genes. On the other hand, we have discovered that Midazolam suppressed chondrogenic differentiation markers at the range of 1-20 μmol/L in human MSCs. Interestingly, the plasma concentrations of benzodiazepine derivatives from clinical samples ranged from 0.1 to 50 μmol/L\textsuperscript{47,48}. These results suggest that administration of Midazolam at clinical dosages suppresses chondrogenic differentiation by inhibiting the levels of chondrogenic-dependent markers.

We also investigated how Midazolam acts on MSCs to suppress their chondrogenic differentiation. Because MSCs were isolated from peripheral tissues, we aimed for the PBR. Early reports showed that PBR is expressed ubiquitously in most types of tissues, including bone marrow\textsuperscript{14} and is required for adipogenic differentiation and MSC proliferation.\textsuperscript{59} It is also known that PBR expresses in murine osteoblasts and osteoclasts, suggesting that PBR may be involved in bone homeostasis.\textsuperscript{50} To confirm that PBR mediated inhibitory effects...
of Midazolam, we used a specific antagonist, PK11195, which has been widely used to study PBR functions.\textsuperscript{18,51} We demonstrated that Midazolam-induced suppression of chondrogenesis was blocked by PK11195 as shown by chondrogenic markers, such as SOX9 and type II collagen, and by the expression of GAG. This suggests that Midazolam has an inhibitory function against MSCs differentiating into chondrocytes through PBR. However, several studies have indicated that certain types of GABA receptor subunits can be detected in murine MSCs, chondrogenic cells, growth plate chondrocytes, cartilage and osteoblasts.\textsuperscript{52-54} It is uncertain whether these subunits are able to assemble to become a functional GABA receptor and whether the GABA receptor can be expressed in hMSCs, which in turn mediate the effect of Midazolam on chondrogenesis. Together, these results suggest that Midazolam acts on hMSCs through PBRs to inhibit chondrogenesis.

At higher doses of PK11195 treatment (higher than 20 \textmu M/L), we observed cell loss (data not shown), which may have been damaging to our conclusion. To rule out this possible off-target effect of PK11195, we used siRNA specific to PBRs to evaluate the function of PBR on the actions of Midazolam in chondrogenesis. Twenty-four hours after transfection of siRNA, the protein level of PBRs was significantly decreased compared with the scrambled control. Midazolam-induced suppression of chondrogenesis was markedly rescued with siRNA-down-regulated PBR in hMSCs. This result further confirmed the role of PBR in mediating the inhibitory effect of Midazolam in chondrogenesis.

The major signalling pathway used to induce chondrogenesis in this study was TGF-\textbeta-induced Smad3 phosphorylation. TGF-\textbeta, a pleiotropic cytokine, is involved in the regulation of cell division and suppression of immune response.\textsuperscript{55} Upon binding of TGF-\textbeta to its receptor, the receptor complex recruits and phosphorylates the carboxy terminus of receptor-regulated Smad proteins (R-Smads: Smad2 and Smad3).\textsuperscript{36,56} Phosphorylated Smads can interact with Smad4 to become a complex, and this complex translocates into the nucleus and turns on gene transcription.\textsuperscript{55} Smad3 is able to activate SOX9 via recruitment of CREB-binding protein/p300.\textsuperscript{46} In addition, TGF-\textbeta/Smad signalling is essential for osteocartilage development, bone homeostasis and MSC fate decision.\textsuperscript{57} Disruption of TGF-\textbeta/Smad signalling in vivo resulted in serious problems in the musculoskeletal system.\textsuperscript{58} Midazolam has been found to inhibit protein phosphorylation. For example, a previous report indicated that Midazolam inhibits platelet activation by inhibiting protein phosphorylation of protein kinase C.\textsuperscript{59} In mouse hippocampal slices, Midazolam was found to inhibit extracellular signal-related kinase 1/2 activity, and this inhibition was likely mediated via N-methyl-d-aspartate receptors, phospholipase C and PKC-dependent signalling.\textsuperscript{60} We therefore proposed that the chondrogenic inhibitory effect of Midazolam was caused by the inhibition of Smad 3 phosphorylation. Indeed, Midazolam can dose-dependently inhibit Smad3 phosphorylation (Figure 6) and this Smad3 phosphorylation inhibition was mediated by PBR, as proved when administration of PK11195 reversed the inhibitory effect of Midazolam. We therefore speculate that the inhibitory effect of Midazolam on TGF-\textbeta-induced Smad 3 phosphorylation is mediated by binding to PBR. Several studies have demonstrated that in most types of tissue, PBR is primarily located in the outer membrane of mitochondria.\textsuperscript{13} In addition to the outer mitochondrial membrane,
PBR was also located in various subcellular regions. Mukherjee and Das first reported that although the amount of [3H]-labelled R05-4864 (another PBR ligand) binding sites was highest in the mitochon- driofrational fraction, the nuclear and cytosolic fractions also contained significant amounts of these binding sites. A study conducted by Kuhlmann and Guilarte discovered that after neural injury, PBR local- ization was in cytosol or perinuclear areas in microglia cells and macrophages. In addition, subcellular localization of PBR was also found in cytosol or in the nuclei of different cell types (i.e. MA-10, MCF-7, and MDA-MB-231), and these nuclear localized PBR was implicated to correlate with cell proliferation and nuclear cholesterol transport. This cytosolic localization of PBR supports our specula- tion that Midazolam can bind with cytosolic PBR to regulate TGF-β1-induced Smad3 phosphorylation, which also occurs in cytosol. Further study of how Midazolam binds to cytosolic PBRs and exerts its function should be investigated.

Taken together, our findings suggest that Midazolam inhibits chondrogenesis via PBR to inhibit TGF-β1 signalling, which in turn suppresses chondrogenesis. This partially explains why this sedative drug can result in congenital malformation of newborns if a pregnant woman is treated with benzodiazepine for anxiety and insomnia. Thus, the future application of these types of drugs must be more thoroughly considered. Further studies to elucidate how these benzodiazepine derivatives interact with their receptors and cause vari- ous outcomes require more sophisticated investigation.

ACKNOWLEDGEMENTS

We thank Ms. Chun-Yi Hsu, Yung-Shan Hsu and Yu-Ting Wu for their excellent technical support and administrative effort on the project. This work was supported mainly by grant from Ministry of Science and Technology, Taiwan (MOST 105-2320-B-006-030) to YKW. This work was also supported, at least in part by the grant from An Nan Hospital-China Medical University (ANHRF104-01) to ECS, Chang Gung Memorial Hospital (Chia Yi, CMRP6G0291) to KCW and grant from Academia Sinica (2396-106-0100) to YKW.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interest.

AUTHOR CONTRIBUTIONS

YCC, KCW, ECS and YKW initiated the project; YCC and KCW designed the experiments and YCC conducted experiments of the project; BMH provided reagents; YCC, KCW, ECS and YKW analysed the results; YCC, KCW, ECS and YKW wrote manuscript; BMH edited the manuscript; YKW and ECS supervised the progress. All authors read and confirmed the final draft of the manuscript.

ORCID

Yang-Kao Wang http://orcid.org/0000-0003-4887-5562

REFERENCES

1. Tobias JD, Leder M. Procedural sedation: a review of sedative agents, monitoring, and management of complications. Saudi J Anaesth. 2011;5:395-410.
2. Mohler H, Fritschy JM, Rudolph U. A new benzodiazepine pharmacol- ogy. J Pharmacol Exp Ther. 2002;300:2-8.
3. Oikolka KT, Ahonen J. Midazolam and other benzodiazepines. Handb Exp Pharmacol. 2008;182:335-360.
4. Swinyard EA, Castellion AW. Anticonvulsant properties of some ben- zodiazepines. J Pharmacol Exp Ther. 1966;151:369-375.
5. Tallman JF, Paul SM, Skolnick P, Gallager DW. Receptors for the age of anxiety: pharmacology of the benzodiazepines. Science. 1980;207:274-281.
6. Bickford PC, Breiderick L. Benzodiazepine modulation of GABAergic responses is intact in the cerebellum of aged F344 rats. Neurosci Lett. 2000;291:187-190.
7. Carmel I, Fares FA, Leschiner S, Scherül B, Weisinger G, Gavish M. Peripheral-type benzodiazepine receptors in the regulation of prolif- eration of MCF-7 human breast carcinoma cell line. Biochem Pharma- col. 1999;58:273-278.
8. Sieghart W. Structure and pharmacology of gamma-aminobutyric acidA receptor subtypes. Pharmacol Rev. 1995;47:181-234.
9. Attack JR. The benzodiazepine binding site of GABA(A) receptors as a target for the development of new anxiolytics. Expert Opin Investig Drugs. 2005;14:601-618.
10. Greenfield LJ Jr. Molecular mechanisms of antiseizure drug activity at GABAA receptors. Seizure. 2013;22:589-600.
11. Li F, Liu J, Liu N, Kuhn LA, Garavito RM, Ferguson-Miller S. Translo- cator protein 18 kDa (TSPO): an old protein with new functions? Biochem Pharmacol. 2008;70:335-360.
12. Papadopoulos V, Baraldi M, Guilarte TR, et al. Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Phar- macol Sci. 2006;27:402-409.
13. Casellas P, Galiegue S, Basile AS. Peripheral benzodiazepine recep- tors and mitochondrial function. Neurochem Int. 2002;40:475-486.
14. Kumar A, Muzik O, Chugani D, Chakraborty P, Chugani HT. PET- derived biodistribution and dosimetry of the benzodiazepine recep- tor-binding radioligand ([11C](R)-PK11195 in children and adults. J Nucl Med. 2010;51:139-144.
15. Krasovskii MD, Jenkins A, Flood P, Kung AY, Hofspring AJ, Harrison NL. General anesthetic potencies of a series of propofol analogs corre- lates with potency of γ-aminobutyric acid (GABA) current at the GABAA receptor but not with lipid solubility. J Pharmacol Exp Ther. 2001;297:338-351.
16. Lin R, Angelin A, Da Settimo F, et al. Genetic analysis of a pBR-independent, direct transporter-modulating mechanism. Trends Pharmacol Sci. 2005;26:3584-3593.
17. Wang M, Wang Z, Zhao L, et al. Macrogli-microglia interactions via TSPO signaling regulates microglial activation in mouse retina. J Neurosci. 2014;34:3793-3806.
18. Walter RB, Pirga JL, Cronk MR, Mayer S, Appelbaum FR, Banker DE. PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood. 2005;106:3584-3593.
19. Qi Z, Li M, He J, et al. Translocator protein mediates the anxiolytic and antidepressant effects of midazolam. Pharmacol Biochem Behav. 2015;139:77-83.
20. Dolovich LR, Addis A, Vaillancourt JM, Power JD, Koren G, Einardon TR. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ. 1998;317:839-843.
21. Laegreid L, Olegard R, Conrad N, Hagberg G, Wahlström J, Abrahamsson L. Congenital malformations and maternal consumption of benzodiazepines: a case-control study. Dev Med Child Neurol. 1990;32:432-441.

22. Deck GM, Nadkarni N, Montouris GD, Lovett A. Congenital malformations in infants exposed to antiepileptic medications in utero at Boston Medical Center from 2003 to 2010. Epilepsy Behav. 2015;51:166-169.

23. Nikizad H, Yon JH, Carter LB, Jevtovic-Todorovic V. Early exposure to general anesthesia causes significant neuronal deletion in the developing rat brain. Ann N Y Acad Sci. 2007;1122:69-82.

24. Buttar HS, Moffatt JH. Pre- and postnatal development of rats following concomitant intrauterine exposure to proopxyphene and chloridiazepoxide. Neurobehav Toxicol Tetratol. 1983;5:549-556.

25. Mehannya SZ, Abdel-Rahman MS, Ahmed YY. Teratogenic effect of cocaine and diazeapm in CF1 mice. Teratology. 1991;43:11-17.

26. Zhang T, Shao H, Xu K, Kuang LT, Chen RF, Xiu HH. Midazolam suppresses osteogenic differentiation of human bone marrow-derived mesenchymal stem cells. Eur Rev Med Pharmacol Sci. 2014;18:1411-1418.

27. Lagana AS, Triolo O, D’Amico V, et al. Management of women with epilepsy: from preconception to post-partum. Arch Gynecol Obstet. 2016;293:493-503.

28. Hung SC, Yang DM, Chang CF, et al. Immortalization without neo- plastic transformation of human mesenchymal stem cells by transduction with HPV16 E6/E7 genes. Int J Cancer. 2004;110:313-319.

29. Tsai CC, Chen CL, Liu HC, et al. Overexpression of hTERT increases stem-like properties and decreases spontaneous differentiation in human mesenchymal stem cell lines. J Biomed Sci. 2010;17:64.

30. Chen WH, Lai MT, Wu ATH, et al. In vitro stage-specific chondrogenesis of mesenchymal stem cells committed to chondrocytes. Arthritis Rheum. 2009;60:450-459.

31. Gao L, McBeath R, Chen CS. Stem cell shape regulates a chondrogenic versus myogenic fate through Rac1 and N-cadherin. Stem Cells. 2010;28:564-572.

32. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. Science. 1999;284:143-147.

33. Woods A, Wang G, Beier F. RhoA/ROCK signaling regulates Sox9 expression and actin organization during chondrogenesis. J Biol Chem. 2005;280:11626-11634.

34. Ikeda T, Kamelkura S, Mabuchi A, et al. The combination of SOX5, SOX6 and SOX9 (the SOX trio) provides signals sufficient for the induction of permanent cartilage. Arthritis Rheum. 2004;50:3561-3573.

35. Kim HJ, Im GL. Electroporation-mediated transfer of Sox trio genes (SOX-5, SOX-6, and SOX-9) to enhance the chondrogenesis of mesenchymal stem cells. Stem Cells Dev. 2011;20:2103-2114.

36. Derynk R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature. 2003;425:577-584.

37. Yang L, Tsang KY, Tang HC, Chan D, Cheah KS. Hypertrophic chondrocytes can become osteoblasts and osteocytes in endochondral bone formation. Proc Natl Acad Sci USA. 2014;111:12097-12102.

38. Zhou X, von der Mark K, Henry S, Norton W, Adams H, de Crombrugghe B. Chondrocytes transdifferentiate into osteoblasts in endochondral bone during development, postnatal growth and fracture healing in mice. PLoS Genet. 2014;10:e1004820.

39. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B. The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev. 2002;16:2813-2826.

40. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B. Sox9 is required for cartilage formation. Nat Genet. 1999;22:85-89.

41. Lefebvre V, Dvir-Ginzberg M. SOX9 and the many facets of its regulation in the chondrocyte lineage. Connect Tissue Res. 2017;58:2-14.

42. Leung VY, Gao B, Leung KK, et al. SOX9 governs differentiation stage-specific gene expression in growth plate chondrocytes via direct concomitant transactivation and repression. PLoS Genet. 2011;7:e1002356. https://doi.org/10.1371/journal.pgen.1002356.

43. Bell DM, Leung KK, Wheatley SC, et al. SOX9 directly regulates the type II collagen gene. Nat Genet. 1997;16:174-178.

44. Ng LJ, Wheatley S, Muscat GE, et al. SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. Dev Biol. 1997;183:108-121.

45. Sekiya I, Tsuji K, Koopman P, et al. SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem. 2000;15:10738-10744.

46. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H. Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem. 2005;280:8343-8350.

47. Bowling AC, Delorenzo RJ. Micromor affinity benzodiazepine receptors: identification and characterization in central nervous system. Science. 1982;216:1247-1250.

48. Wilms H, Claassen J, Rohl C, Sievers J, Deuschl G, Lucius R. Involvement of benzodiazepine receptors in neuroinflammatory and neurodegenerative diseases: evidence from activated microglial cells in vitro. Neurobiol Dis. 2003;14:417-424.

49. Lee DH, Kang SK, Lee RH, et al. Effects of peripheral benzodiazepine receptor ligands on proliferation and differentiation of human mesenchymal stem cells. J Cell Physiol. 2004;198:91-99.

50. Kam WW, Meikle SR, Zhou H, et al. The 18 kDa translocator protein (peripheral benzodiazepine receptor) expression in the bone of normal, osteoporotetic or low calcium diet treated mice. PLoS ONE. 2012;7:e30623. https://doi.org/10.1371/journal.pone.0030623.

51. Bono F, Lamarche I, Prabonnaud V, Le Fur G, Herbert JM. Peripheral benzodiazepine receptor agonists exhibit potent antiapoptotic activities. Biochem Biophys Res Commun. 1999;265:457-461.

52. Mizuta K, Osawa Y, Mizuta F, Xu D, Emala CW. Functional expression of GABAB receptors in airway epithelium. Am J Respir Cell Mol Biol. 2006;39:296-304.

53. Takahata Y, Hinoi E, Takarada T, Nakamura Y, Ogawa S, Yoneda Y. Positive regulation by gamma-aminobutyric acid B receptor subunit-1 of chondrogenesis through acceleration of nuclear translocation of activating transcription factor-4. J Biol Chem. 2012;287:33293-33303.

54. Tamayama T, Maemura K, Kanbara K, Gallager DW. Expression of GABA(A) and GABA(B) receptors in rat growth plate chondrocytes: activation of the GABA receptors promotes proliferation of mouse chondrogenic ATDC5 cells. Mol Cell Biochem. 2005;273:117-126.

55. Schnaper HW, Hayashida T, Hubbach SC, Poncelet AC. TGF-beta signal transduction and mesangial cell fibrogenesis. Am J Physiol Renal Physiol. 2003;284:F243-F252.

56. Cleary MA, van Osch GJ, Brama PA, Hellingman CA, Narcisi R, GFG, TGFβ and Wnt crosstalk: embryonic to in vitro cartilage development from mesenchymal stem cells. J Tissue Eng Regen Med. 2015;9:332-342.

57. Crane JL, Cao X. Bone marrow mesenchymal stem cells and TGF-beta signaling in bone remodeling. J Clin Invest. 2014;124:466-472.

58. Zhang X, Ma Y, You T, et al. Roles of TGF-beta/Smad signaling pathway in pathogenesis and development of gluteal muscle contracture. Connect Tissue Res. 2015;56:9-17.

59. Sheu JR, Hsiao G, LukHN, et al. Mechanisms involved in the platelet activity of Midazolam in human platelet. Anesthesiology. 2002;96:651-658.

60. Gao H, Han M, Zhang L, et al. Anesthetics inhibit extracellular signal-related kinase 1/2 phosphorylation via NMDA receptor, phospholipase C and protein kinase C in mouse hippocampal slices. Neurochem Int. 2017;103:36-44.

61. Mukherjee S, Das SK. Subcellular distribution of “peripheral type” biding sites for [3 h]r05-4864 in guinea pig lung. J Biol Chem. 1989;264:16713-16718.

62. Kuhlmann AC, Guirarte TR. Cellular and subcellular localization of peripheral benzodiazepine receptor after trimethyltin neurotoxicity. J Neurochem. 2000;74:1694-1704.
63. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, Papadopoulos V. Peripheral-type benzodiazepine receptor (PBR) in human breast cancer. Cancer Res. 1999;59:831-842.

SUPPORTING INFORMATION

Additional Supporting Information may be found online in the supporting information tab for this article.

How to cite this article: Chen Y-C, Wu K-C, Huang B-M, So EC, Wang Y-K. Midazolam inhibits chondrogenesis via peripheral benzodiazepine receptor in human mesenchymal stem cells. J Cell Mol Med. 2018;22:2896–2907. https://doi.org/10.1111/jcmm.13584